IL144202A0 - Baff, related blocking agents and their use in the stimulation and inhibition of b-cells and immunoglobulins in immune responses - Google Patents

Baff, related blocking agents and their use in the stimulation and inhibition of b-cells and immunoglobulins in immune responses

Info

Publication number: IL144202A0
Authority: IL; Israel
Prior art keywords: cell growth; baff; immunoglobulin production; ligand; cell
Prior art date: 1999-01-25

Application number

IL14420200A

Other languages

English (en)

Original Assignee

Biogen Inc

Apotech Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-25

Filing date

2000-01-25

Publication date

2002-05-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26815006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL144202(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-01-25 Application filed by Biogen Inc, Apotech Sa filed Critical Biogen Inc

2002-05-23 Publication of IL144202A0 publication Critical patent/IL144202A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0325—Animal model for autoimmune diseases
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0368—Animal model for inflammation
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0381—Animal model for diseases of the hematopoietic system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Environmental Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biodiversity & Conservation Biology (AREA)
Animal Husbandry (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Gastroenterology & Hepatology (AREA)
Virology (AREA)
Toxicology (AREA)
Cardiology (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Physics & Mathematics (AREA)

IL14420200A 1999-01-25 2000-01-25 Baff, related blocking agents and their use in the stimulation and inhibition of b-cells and immunoglobulins in immune responses IL144202A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US11716999P	1999-01-25	1999-01-25
US14322899P	1999-07-09	1999-07-09
PCT/US2000/001788 WO2000043032A2 (en)	1999-01-25	2000-01-25	Baff, inhibitors thereof and their use in the modulation of b-cell response

Publications (1)

Publication Number	Publication Date
IL144202A0 true IL144202A0 (en)	2002-05-23

Family

ID=26815006

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
IL14420200A IL144202A0 (en)	1999-01-25	2000-01-25	Baff, related blocking agents and their use in the stimulation and inhibition of b-cells and immunoglobulins in immune responses
IL144202A IL144202A (en)	1999-01-25	2001-07-09	Use of soluble baff or of an antibody specific for soluble baff for the preparation of a pharmaceutical composition for treating system-related diseases
IL200498A IL200498A0 (en)	1999-01-25	2009-08-20	Use of soluble baff or of an antibody secific for soluble baff for the preparation of a

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
IL144202A IL144202A (en)	1999-01-25	2001-07-09	Use of soluble baff or of an antibody specific for soluble baff for the preparation of a pharmaceutical composition for treating system-related diseases
IL200498A IL200498A0 (en)	1999-01-25	2009-08-20	Use of soluble baff or of an antibody secific for soluble baff for the preparation of a

Country Status (29)

Country	Link
US (1)	US6869605B2 (no)
EP (5)	EP2298332B1 (no)
JP (5)	JP5066314B2 (no)
KR (1)	KR100834809B1 (no)
CN (1)	CN100340292C (no)
AT (2)	ATE247482T1 (no)
AU (1)	AU762839B2 (no)
BR (1)	BR0007719A (no)
CA (1)	CA2360062A1 (no)
CY (2)	CY1107453T1 (no)
CZ (1)	CZ299819B6 (no)
DE (1)	DE60004635T2 (no)
DK (2)	DK1146892T3 (no)
EA (1)	EA006108B1 (no)
EE (1)	EE05699B1 (no)
ES (1)	ES2204528T3 (no)
HK (1)	HK1040628B (no)
HU (1)	HUP0105283A3 (no)
IL (3)	IL144202A0 (no)
IS (1)	IS5993A (no)
MX (1)	MXPA01007464A (no)
NO (2)	NO20013641L (no)
NZ (1)	NZ513284A (no)
PL (1)	PL198934B1 (no)
PT (2)	PT1146892E (no)
SI (1)	SI1146892T1 (no)
SK (1)	SK286665B6 (no)
TR (2)	TR200102147T2 (no)
WO (1)	WO2000043032A2 (no)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8212004B2 (en)	1999-03-02	2012-07-03	Human Genome Sciences, Inc.	Neutrokine-alpha fusion proteins
US6812327B1 (en)	1996-10-25	2004-11-02	Human Genome Sciences, Inc.	Neutrokine-alpha polypeptides
US20030175208A1 (en) *	1996-10-25	2003-09-18	Human Genome Sciences, Inc.	Neutrokine-alpha and neutrokine-alpha splice variant
US6689579B1 (en)	1996-10-25	2004-02-10	Human Genome Sciences, Inc.	Polynucleotides encoding neutrokine-α
EP0878552A1 (en)	1997-05-13	1998-11-18	Erasmus Universiteit Rotterdam	Molecular detection of chromosome aberrations
AU3516899A (en)	1998-05-04	1999-11-23	Dako A/S	Method and probes for the detection of chromosome aberrations
GB9828628D0 (en)	1998-12-23	1999-02-17	Glaxo Group Ltd	Novel ligand
US7833529B1 (en)	1999-01-07	2010-11-16	Zymogenetics, Inc.	Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en) *	1999-01-25	2003-05-22	Mackay Fabienne	BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20050100548A1 (en) *	2001-07-24	2005-05-12	Biogen Idec Ma Inc.	BAFF, inhibitors thereof and their use in the modulation of B-cell response
PT1146892E (pt) *	1999-01-25	2003-12-31	Biogen Inc	Fabf seus inibidores e o seu uso na modulacao da resposta as celulas b
WO2000068378A1 (en) *	1999-05-06	2000-11-16	National Jewish Medical And Research Center	Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
NZ517782A (en) *	1999-08-17	2004-01-30	Biogen Inc	A beta-cell activating factor receptor belonging to the TNF family is used as a pharmaceutical agent and in the treatment of disease
UA74798C2 (uk)	1999-10-06	2006-02-15	Байоджен Айдек Ма Інк.	Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
PT1255558E (pt) *	2000-02-16	2006-11-30	Genentech Inc	Anticorpos anti-april e células hibridoma
EP2281843B1 (en)	2000-06-16	2016-10-12	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to BLyS
US7879328B2 (en)	2000-06-16	2011-02-01	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator
US7220840B2 (en)	2000-06-16	2007-05-22	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator protein
JP2004532604A (ja) *	2000-08-18	2004-10-28	ダイアックスコーポレーション	Ｂリンパ球刺激因子タンパク質（ＢＬｙＳ）のための結合性ポリペプチド
AU2001288301A1 (en) *	2000-08-18	2002-03-04	Human Genome Sciences, Inc.	Binding polypeptides and methods based thereon
UA83458C2 (uk)	2000-09-18	2008-07-25	Байоджен Айдек Ма Інк.	Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
DK1385882T3 (da) *	2001-05-11	2008-02-11	Amgen Inc	Peptider og relaterede molekyler, der binder til TALL-1
SI1436003T1 (sl)	2001-05-24	2010-02-26	Zymogenetics Inc	TACI-imunoglobulinski fuzijski proteini
IL160127A0 (en) *	2001-08-03	2004-06-20	Genentech Inc	Tacis and br3 polypeptides and uses thereof
AR035119A1 (es)	2001-08-16	2004-04-14	Lilly Co Eli	Anticuerpos humanos antagonistas anti-htnfsf13b
US7825089B2 (en)	2001-10-24	2010-11-02	National Jewish Health	Three-dimensional structures of TALL-1 and its cognate receptors and modified proteins and methods related thereto
WO2003072713A2 (en) *	2002-02-21	2003-09-04	Biogen Idec Ma Inc.	Use of bcma as an immunoregulatory agent
MXPA05000940A (es) *	2002-07-25	2005-05-16	Genentech Inc	Anticuerpos taci y su uso.
AU2003277828B2 (en)	2002-10-29	2009-06-04	Anaphore, Inc.	Trimeric binding proteins for trimeric cytokines
US7553930B2 (en)	2003-01-06	2009-06-30	Xencor, Inc.	BAFF variants and methods thereof
WO2004074511A1 (en) *	2003-02-21	2004-09-02	Garvan Institute Of Medical Research	Diagnosis and treatment of baff-mediated autoimmune diseases and cancer
EP1606312A2 (en) *	2003-03-07	2005-12-21	Xencor Inc.	Baff mutants with at least one amino acid substitution and methods of their production
NZ543174A (en)	2003-03-28	2008-09-26	Biogen Idec Inc	Truncated BAFF receptors
EP1631313B1 (en) *	2003-06-05	2015-03-11	Genentech, Inc.	Combination therapy for b cell disorders
US20050163775A1 (en) *	2003-06-05	2005-07-28	Genentech, Inc.	Combination therapy for B cell disorders
EP1675609A1 (en)	2003-10-20	2006-07-05	Biogen Idec MA Inc.	Therapeutic regimens for baff antagonists
WO2005075511A1 (en)	2004-01-29	2005-08-18	Genentech, Inc.	Variants of the extracellular domain of bcma and uses thereof
US20080050381A1 (en) *	2004-08-31	2008-02-28	Tsutomu Takeuchi	Antihuman Baff Antibody
WO2006044582A2 (en)	2004-10-13	2006-04-27	The Washington University	Use of baff to treat sepsis
AU2006209237B2 (en) *	2005-01-28	2010-06-24	Biogen Ma Inc.	Use of BAFF to treat Th2-mediated conditions
US20090232808A1 (en) *	2005-01-28	2009-09-17	Apollo Life Sciences Limited	Molecules and chimeric molecules thereof
RU2007142523A (ru) *	2005-05-18	2009-06-27	БИОГЕН ИДЕК Инк. (US)	Способы лечения фиброзных состояний
AR059025A1 (es)	2005-08-09	2008-03-12	Zymogenetics Inc	Metodos para el tratamiento y prevencion de proliferacion de celulas anormales utilizando moleculas de fusion taci
WO2007019575A2 (en)	2005-08-09	2007-02-15	Zymogenetics, Inc.	Methods for treating b-cell malignancies using taci-ig fusion molecule
KR20080074120A (ko) *	2005-10-13	2008-08-12	휴먼 게놈 사이언시즈, 인코포레이티드	자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
US9168286B2 (en)	2005-10-13	2015-10-27	Human Genome Sciences, Inc.	Methods and compositions for use in treatment of patients with autoantibody positive disease
US9726673B2 (en)	2005-11-23	2017-08-08	Genentech, Inc.	Methods and compositions related to B cell assays
WO2007123765A2 (en)	2006-03-31	2007-11-01	Human Genome Sciences Inc.	Neutrokine-alpha and neutrokine-alpha splice variant
AR060935A1 (es)	2006-05-15	2008-07-23	Ares Trading Sa	Metodos para tratar enfermedades autoinmunes utilizando una molecula de fusion taci- ig
EP2396035A4 (en) *	2009-02-12	2012-09-12	Human Genome Sciences Inc	USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE
KR101717809B1 (ko) *	2010-03-11	2017-03-17	질레드 코네티컷 인코포레이티드	이미다조피리딘 ｓｙｋ 억제제
WO2013171296A1 (en)	2012-05-16	2013-11-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Diagnostic and treatment of sarcoidosis
CZ304104B6 (cs) *	2012-08-22	2013-10-23	Masarykova Univerzita	B-bunecný aktivující faktor pro zvýsení sliznicní imunity kojencu a prípravek jej obsahující
US9458246B2 (en)	2013-03-13	2016-10-04	Amgen Inc.	Proteins specific for BAFF and B7RP1
PH12022550138A1 (en)	2013-03-13	2023-03-06	Amgen Inc	Proteins specific for baff and b7rp1 and uses thereof
WO2014140243A1 (en)	2013-03-15	2014-09-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method and pharmaceutical composition for use in the treatment and prediction of myocardial infarction
KR101493592B1 (ko)	2013-04-29	2015-02-17	부산대학교 산학협력단	Ｓｏｃｓ3 단백질을 이용한 ｂａｆｆ 연관 면역질환 치료제 스크리닝 방법
CN105792646B (zh)	2013-11-19	2018-03-02	瑞泽恩制药公司	具有人源化的b细胞活化因子基因的非人动物
UY35898A (es)	2013-12-23	2015-07-31	Gilead Sciences Inc	?compuestos inhibidores de syk y composiciones que los comprenden?.
US10435474B2 (en)	2013-12-24	2019-10-08	Ossianix, Inc.	Baff selective binding compounds and related methods
EA033604B1 (ru)	2014-01-31	2019-11-08	Boehringer Ingelheim Int	Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид
AR104368A1 (es)	2015-04-03	2017-07-19	Lilly Co Eli	Anticuerpos biespecíficos anti-cd20- / anti-baff
US12023367B2 (en)	2015-06-19	2024-07-02	University Of Louisville Research Foundation, Inc.	Immunomodulation for the long term prevention and treatment of autoimmune diseases and foreign tissue rejection
CN107328620B (zh) *	2017-06-23	2020-06-05	浙江普罗亭健康科技有限公司	用于流式细胞技术的封闭缓冲液及试剂盒
WO2019126366A2 (en) *	2017-12-19	2019-06-27	The Johns Hopkins University	Baff therapy to promote anti- tumor immunity
US20210238295A1 (en) *	2018-04-26	2021-08-05	University Of Virginia Patent Foundation	Compositions and methods for treating abdominal aortic aneurysm
MX2021010131A (es)	2019-02-22	2021-11-18	Kronos Bio Inc	Formas sólidas de pirazinas condensadas a manera de inhibidores de syk.

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5176996A (en)	1988-12-20	1993-01-05	Baylor College Of Medicine	Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en)	1989-06-05	1993-10-26	Gilead Sciences, Inc.	Exonuclease-resistant oligonucleotides
US5264564A (en)	1989-10-24	1993-11-23	Gilead Sciences	Oligonucleotide analogs with novel linkages
US5595721A (en) *	1993-09-16	1997-01-21	Coulter Pharmaceutical, Inc.	Radioimmunotherapy of lymphoma using anti-CD20
US6541224B2 (en) *	1996-03-14	2003-04-01	Human Genome Sciences, Inc.	Tumor necrosis factor delta polypeptides
ES2210354T3 (es)	1996-03-14	2004-07-01	Human Genome Sciences, Inc.	Factor de necrosis tumoral humano delta y epsilon.
NZ334309A (en) *	1996-10-25	2000-08-25	Human Genome Sciences Inc	Neutrokine alpha protein, a member of the TNF family, and its use in treating and/or detecting immune disorders
SE505941C2 (sv)	1996-10-29	1997-10-27	Bjoern Hellstroem	Klämskyddslist
WO1998027114A2 (en) *	1996-12-17	1998-06-25	Schering Corporation	Mammalian cell surface antigens; related reagents
US5969102A (en) *	1997-03-03	1999-10-19	St. Jude Children's Research Hospital	Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en) *	1997-04-02	1998-10-02	Smithkline Beecham Corporation	A tnf homologue, tl5
CA2292899A1 (en)	1997-06-06	1998-12-10	Regeneron Pharmaceuticals, Inc.	Ntn-2 member of tnf ligand family
IL133315A0 (en) *	1997-06-06	2001-04-30	Regeneron Pharma	Ntn-2 member of tnf ligand family
AU9376498A (en)	1997-09-05	1999-03-22	University Of Washington	Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
CN1269832A (zh)	1997-09-12	2000-10-11	阿普泰克研究与开发公司	K－配体－新的免疫系统蛋白
CN1195849C (zh)	1997-09-12	2005-04-06	阿普泰克R&D公司	April－具有生长效应的新的蛋白质
WO1999026463A2 (en)	1997-11-26	1999-06-03	Eli Lilly And Company	Tnf ligand family gene
US6297367B1 (en) *	1997-12-30	2001-10-02	Chiron Corporation	Polynucleotide encoding TNFL1
AU2093499A (en)	1997-12-30	1999-07-19	Chiron Corporation	Members of tnf and tnfr families
WO2000026244A2 (en)	1998-11-04	2000-05-11	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	A novel tumor necrosis factor family member, drl, and related compositions and methods
GB9828628D0 (en)	1998-12-23	1999-02-17	Glaxo Group Ltd	Novel ligand
DK1141274T4 (en)	1999-01-07	2015-01-19	Zymogenetics Inc	Soluble receptor BR43x2 and method of use thereof in therapy
PT1146892E (pt) *	1999-01-25	2003-12-31	Biogen Inc	Fabf seus inibidores e o seu uso na modulacao da resposta as celulas b
US6475986B1 (en)	1999-02-02	2002-11-05	Research Development Foundation	Uses of THANK, a TNF homologue that activates apoptosis
AU777536B2 (en)	1999-02-23	2004-10-21	Human Genome Sciences, Inc.	Neutrokine-alpha and neutrokine-alpha splice variant
JP2002541779A (ja)	1999-02-24	2002-12-10	ザジュネラルホスピタルコーポレーション	シグナル伝達中間体のクローニング方法
WO2000068378A1 (en)	1999-05-06	2000-11-16	National Jewish Medical And Research Center	Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
CA2399387C (en) *	2000-02-11	2015-11-03	Biogen, Inc.	Heterologous polypeptide of the tnf family
EP2281843B1 (en)	2000-06-16	2016-10-12	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to BLyS
WO2002018620A2 (en)	2000-08-15	2002-03-07	Human Genome Sciences, Inc.	Neutrokine-alpha and neutrokine-alpha splice variant
CA2467521A1 (en)	2001-11-16	2003-07-10	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to blys

2000
- 2000-01-25 PT PT00909970T patent/PT1146892E/pt unknown
- 2000-01-25 AT AT00909970T patent/ATE247482T1/de active
- 2000-01-25 PL PL349772A patent/PL198934B1/pl unknown
- 2000-01-25 NZ NZ513284A patent/NZ513284A/en not_active IP Right Cessation
- 2000-01-25 SI SI200030207T patent/SI1146892T1/xx unknown
- 2000-01-25 EP EP10180420.1A patent/EP2298332B1/en not_active Expired - Lifetime
- 2000-01-25 WO PCT/US2000/001788 patent/WO2000043032A2/en active Application Filing
- 2000-01-25 MX MXPA01007464A patent/MXPA01007464A/es active IP Right Grant
- 2000-01-25 DE DE60004635T patent/DE60004635T2/de not_active Expired - Fee Related
- 2000-01-25 AT AT03018879T patent/ATE515267T1/de active
- 2000-01-25 EP EP10181337A patent/EP2319527A3/en not_active Ceased
- 2000-01-25 HK HK02102203.7A patent/HK1040628B/en not_active IP Right Cessation
- 2000-01-25 CA CA002360062A patent/CA2360062A1/en not_active Abandoned
- 2000-01-25 DK DK00909970T patent/DK1146892T3/da active
- 2000-01-25 TR TR2001/02147T patent/TR200102147T2/xx unknown
- 2000-01-25 HU HU0105283A patent/HUP0105283A3/hu unknown
- 2000-01-25 KR KR1020017009356A patent/KR100834809B1/ko not_active Expired - Lifetime
- 2000-01-25 EE EEP200100386A patent/EE05699B1/xx unknown
- 2000-01-25 AU AU32142/00A patent/AU762839B2/en not_active Expired
- 2000-01-25 IL IL14420200A patent/IL144202A0/xx unknown
- 2000-01-25 CZ CZ20012696A patent/CZ299819B6/cs not_active IP Right Cessation
- 2000-01-25 PT PT03018879T patent/PT1415659E/pt unknown
- 2000-01-25 EP EP03018879A patent/EP1415659B9/en not_active Revoked
- 2000-01-25 DK DK03018879.1T patent/DK1415659T3/da active
- 2000-01-25 BR BR0007719-4A patent/BR0007719A/pt not_active Application Discontinuation
- 2000-01-25 JP JP2000594485A patent/JP5066314B2/ja not_active Expired - Lifetime
- 2000-01-25 EP EP15174329.1A patent/EP2974736A1/en not_active Withdrawn
- 2000-01-25 ES ES00909970T patent/ES2204528T3/es not_active Expired - Lifetime
- 2000-01-25 EP EP00909970A patent/EP1146892B1/en not_active Revoked
- 2000-01-25 EA EA200100822A patent/EA006108B1/ru not_active IP Right Cessation
- 2000-01-25 CN CNB008054878A patent/CN100340292C/zh not_active Expired - Lifetime
- 2000-01-25 SK SK1044-2001A patent/SK286665B6/sk not_active IP Right Cessation
2001
- 2001-01-25 TR TR2004/03498T patent/TR200403498T2/xx unknown
- 2001-07-06 IS IS5993A patent/IS5993A/is unknown
- 2001-07-09 IL IL144202A patent/IL144202A/en not_active IP Right Cessation
- 2001-07-24 US US09/911,777 patent/US6869605B2/en not_active Expired - Fee Related
- 2001-07-24 NO NO20013641A patent/NO20013641L/no not_active Application Discontinuation
2003
- 2003-11-14 CY CY20031101083T patent/CY1107453T1/el unknown
2008
- 2008-11-27 JP JP2008303135A patent/JP4955642B2/ja not_active Expired - Fee Related
2009
- 2009-08-20 IL IL200498A patent/IL200498A0/en unknown
2011
- 2011-10-05 CY CY20111100946T patent/CY1112458T1/el unknown
2012
- 2012-01-24 JP JP2012012379A patent/JP2012087145A/ja not_active Withdrawn
- 2012-03-29 JP JP2012077812A patent/JP2012126749A/ja active Pending
- 2012-04-27 NO NO20120524A patent/NO20120524A1/no not_active Application Discontinuation
2014
- 2014-04-24 JP JP2014090152A patent/JP2014141527A/ja active Pending

Also Published As

Publication number	Publication date
NO20013641D0 (no)	2001-07-24
JP2012126749A (ja)	2012-07-05
EE05699B1 (et)	2014-02-17
JP2009102326A (ja)	2009-05-14
IL144202A (en)	2010-04-29
IS5993A (is)	2001-07-06
EP2319527A2 (en)	2011-05-11
JP2014141527A (ja)	2014-08-07
CZ299819B6 (cs)	2008-12-03
JP5066314B2 (ja)	2012-11-07
SK286665B6 (sk)	2009-03-05
SK10442001A3 (sk)	2002-02-05
NZ513284A (en)	2003-10-31
PT1415659E (pt)	2011-10-13
WO2000043032A2 (en)	2000-07-27
EP1146892A2 (en)	2001-10-24
EP1415659A1 (en)	2004-05-06
AU762839B2 (en)	2003-07-03
MXPA01007464A (es)	2003-06-06
PL349772A1 (en)	2002-09-09
SI1146892T1 (en)	2004-02-29
ATE515267T1 (de)	2011-07-15
IL200498A0 (en)	2011-07-31
KR100834809B1 (ko)	2008-06-05
PT1146892E (pt)	2003-12-31
ATE247482T1 (de)	2003-09-15
EP1415659B1 (en)	2011-07-06
AU3214200A (en)	2000-08-07
HK1040628B (en)	2005-10-14
CA2360062A1 (en)	2000-07-27
BR0007719A (pt)	2001-11-13
JP2012087145A (ja)	2012-05-10
EP2298332A1 (en)	2011-03-23
EE200100386A (et)	2002-12-16
DK1415659T3 (da)	2011-10-03
ES2204528T3 (es)	2004-05-01
DE60004635T2 (de)	2004-06-09
DE60004635D1 (de)	2003-09-25
EA200100822A1 (ru)	2002-02-28
TR200102147T2 (tr)	2002-04-22
EP2974736A1 (en)	2016-01-20
HUP0105283A3 (en)	2004-08-30
EP2319527A3 (en)	2011-10-12
EA006108B1 (ru)	2005-08-25
EP2298332B1 (en)	2015-07-08
EP1146892B1 (en)	2003-08-20
JP2002535285A (ja)	2002-10-22
PL198934B1 (pl)	2008-08-29
CN100340292C (zh)	2007-10-03
EP1415659B9 (en)	2012-02-15
CY1112458T1 (el)	2015-12-09
WO2000043032A3 (en)	2000-12-14
NO20120524A1 (no)	2012-04-27
NO20013641L (no)	2001-09-25
CN1347326A (zh)	2002-05-01
HUP0105283A2 (hu)	2002-04-29
CY1107453T1 (el)	2012-05-23
KR20010105331A (ko)	2001-11-28
HK1065724A1 (en)	2005-03-04
CZ20012696A3 (cs)	2001-10-17
TR200403498T2 (tr)	2005-03-21
US20020037852A1 (en)	2002-03-28
JP4955642B2 (ja)	2012-06-20
HK1040628A1 (en)	2002-06-21
DK1146892T3 (da)	2003-11-24
US6869605B2 (en)	2005-03-22

Publication	Publication Date	Title
IL144202A0 (en)	2002-05-23	Baff, related blocking agents and their use in the stimulation and inhibition of b-cells and immunoglobulins in immune responses
ATE212038T1 (de)	2002-02-15	Humanisierte monoklonale anti-cd40 antikörper und fragmente zur hemmung der b-zellaktivierung
Peters et al.	1988	Accelerated fractionation in the radiation treatment of head and neck cancer—a critical comparison of different strategies
Khoo et al.	2007	Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies
WO2005044854A3 (en)	2005-08-11	Antagonist anti-cd40 monoclonal antibodies and methods for their use
SI1684805T1 (sl)	2010-11-30	Uporaba antagonističnih anti CD monoklonskih protiteles za zdravljenje multiplega mieloma
EP1717251A3 (en)	2007-11-07	Methods of therapy for B-cell malignancies using human anti-CD40 antibodies
EP1680141B8 (en)	2011-01-12	Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
WO2004068931A3 (en)	2005-03-24	Amphiregulin antibodies and their use to treat cancer and psoriasis
SI1490407T1 (sl)	2007-08-31	Indukcija antitumorske CTL imunosti z in vivo sproĹľitvijo 4-1BB in/ali CD40
CA2401604A1 (en)	2001-09-07	Method of treating cancer with anti-neurotrophin agents
PL401886A1 (pl)	2013-05-27	Neutralizujace o wysokim powinowactwie izolowane ludzkie przeciwcialo anty-TNF-alfa, zastosowanie tego przeciwciala, krysztal zawierajacy ludzkie przeciwcialo anty-TNF-alfa i preparat zawierajacy ten krysztal
WO2005044304A3 (en)	2005-08-25	Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
ATE516819T1 (de)	2011-08-15	Verfahren zur behandlung von b-zell-bedingtem krebs
JP2004517611A5 (no)	2005-12-22
ATE348808T1 (de)	2007-01-15	Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten
EP1137658A4 (en)	2003-01-29	METHOD FOR MODULATING TUMOR NECROSIS FACTOR -g (a) -INDUCTED EXPRESSION OF CELL ADHESION MOLECULES